Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH
Ancillary Nocturnal Urinary Symptom Investigation in the TRIUMPH Trial
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed tocompare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonistbladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinaryincontinence and either normal or mildly impaired cognitive function at baseline.
研究概览
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Ann Chang
- 邮箱:ann.chang@ucsf.edu
研究联系人备份
- 姓名:Alison Huang, MD, MAS, MPhil
- 电话号码:(415) 514-8697
- 邮箱:alison.huang@ucsf.edu
学习地点
-
-
California
-
San Francisco、California、美国、94115
- 招聘中
- University of California San Francisco
-
接触:
- Claudia Vila Manes
- 电话号码:415-885-7547
- 邮箱:claudia.vilamanes@ucsf.edu
-
接触:
- Amy Zhang
- 电话号码:(415) 885-7547
- 邮箱:amy.zhang4@ucsf.edu
-
首席研究员:
- Alison Huang, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Aged 60 years or older at the time of enrollment
- Female sex at birth, without surgical or hormonal gender re-assignment therapy
- Able to walk to the bathroom and use the toilet without assistance
- Report urinary incontinence starting at least 3 months prior to screening
- Report that at least half of incontinence episodes occur with a sudden or strong sensation of urgency
- Report 2 or more urgency incontinence episodes over a 7-day period
- Willing to provide informed consent and adhere to study procedures throughout the length of the study
Exclusion Criteria:
- Prior clinician diagnosis of dementia, or a Montreal Cognitive Assessment (MOCA) score of 17 or lower on screening cognitive evaluation
- Current use of anticholinergic, beta-3-adrenergic agonist, or other medication designed to improve urgency incontinence symptoms, or use in the past 1 month
- Initiation, discontinuation, or dose change of dementia medications (such as donepezil, galantamine, memantine, rivastigmine) in the past 1 month (but candidates on stable doses are eligible)
- Initiation, discontinuation, or dose change of other drugs with strong anticholinergic effects (based on the Beers List) in the past 1 month (but candidates on stable doses are eligible)
- Initiation, discontinuation, or dose change of other drugs that can affect urinary frequency, including diuretics, in the past 1 month (but candidates on stable doses are eligible)
- Current urinary tract infection (UTI) based on screening urinalysis and culture (but candidates can re-present for re-screening after undergoing treatment for UTI)
- History of allergy or sensitivity to either of the study medications or an ingredient in the placebo or study medication capsule
- Severe hepatic impairment (Child-Pugh score B or greater) or renal impairment (creatinine clearance <30 mL/min) as a contraindication to both study medications
- Current bladder obstruction or urinary retention (defined by symptoms suggesting difficulty emptying the bladder in addition to postvoid residual urine volume greater than 150 cc by portable bladder ultrasound)
- Uncontrolled hypertension (based on measured systolic blood pressure greater than 180 or diastolic blood pressure greater than 110 mmHg) as a contraindication to beta-3-adrenergic therapy
- Self-reported history of gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, or toxic megacolon as contraindications for anticholinergic bladder therapy
- Use of drugs with adverse interactions with one of the study medications in the past 1 month, including potent CYP3A4 inhibitors, hepatic enzyme metabolism inducers, narrow therapeutic index drugs metabolized by CYP2D6, or intention to start taking one of these medications during the study treatment period
- History of bladder surgery, invasive intra-vesical therapy, or bulk bladder injections in the past 3 months (more remote surgery will not be exclusionary), or intention to undergo one of these procedures in the study treatment period
- Use of other specialized incontinence therapy (electrostimulation, pelvic physiotherapy, formal behavioral therapy overseen by certified practitioners) in the past 3 months (more remote therapy will not be exclusionary), or intention to undergo one of these procedures in the study treatment period
- Inability to sign informed consent or complete questionnaires, interviews, or study testing in English
- Other condition that would prevent the participant from completing study procedures, in the opinion of the investigators (e.g., uncontrolled psychosis)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Anticholinergic bladder medication plusbehavioral self-management education
Tolterodine tartrate is a muscarinic receptor antagonist designed to treat urgency incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urge suppression |
Anticholinergic |
|
有源比较器:Beta-3-adrenergic agonist medication plusbehavioral self-management education
Mirabegron, currently sold under the brand name Mybetriq by Astellas Pharma, is a selective beta-3-adrenergic receptor agonist approved for treatment of urgency urinary incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression. |
Beta-3-adrenergic agonist |
|
安慰剂比较:Placebo medication plus behavioral self-management education
Microcrystalline cellulose placebo encapsulated to appear identical to tolterodine and mirabegron medication will be prepared by a compounding pharmacy. Behavioral self-management education includes written education about time duration, lifestyle changes, pelvic floor muscle exercises, and urge suppression. |
matching placebo pill |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in nocturnal urination frequency over 6 months (24 weeks) of treatment, based on a validated voiding diary.
大体时间:Baseline to 6 months
|
Frequency of nocturnal urination will be assessed using a standardized, 7-day voiding diary. |
Baseline to 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in nocturnal urinary incontinence frequency over 6 months (24 weeks) of treatment, based on a validated voiding diary.
大体时间:Baseline to 6 months
|
Frequency of nocturnal urination will be assessed using a standardized, 7-day voiding diary. |
Baseline to 6 months
|
|
Change in global sleep quality score over 6 months (24 weeks) of treatment.
大体时间:Baseline to 6 months
|
Perceived sleep quality will be assessed using the Pittsburgh Sleep Quality Index(PSQI), an 18-item validated questionnaire designed to assess sleep quality, latency, efficiency, and problems over a one-week period. Score range: 0-21, with higher scores indicating a worse outcome. |
Baseline to 6 months
|
|
Change in daytime sleepiness score over 6 months (24 weeks) of treatment.
大体时间:Baseline to 6 months
|
Daytime sleepiness will be assessed using the Epworth Sleepiness Scale (ESS), an 8-item questionnaire assessing the level of general sleepiness during real-life situations in order to distinguish excessive daytime sleepiness from normal daytime sleepiness. Score range: 0-24, with higher scores indicating a worse outcome. |
Baseline to 6 months
|
|
Change in sleep efficiency over 6 months (24 weeks) of treatment, based on the PSQI sleep efficiency score.
大体时间:Baseline to 6 months
|
Sleep efficiency will be assessed based on questions 1, 3, and 4 of the Pittsburgh Sleep Quality Index (PSQI). Score range: 0-3, with higher scores indicating a worse sleep efficiency. |
Baseline to 6 months
|
|
Change in depression symptoms over 6 months (24 weeks) of treatment.
大体时间:Baseline to 6 months
|
Depression symptoms will be assessed using the 15-item short form of the GeriatricDepression Scale-15 (GDS-15), which assesses symptoms of depression over a 1-week period. Score range: 0-24, with higher scores indicating a worse outcome. Score range: 0-15, with higher scores indicating a worse outcome. |
Baseline to 6 months
|
|
Change in anxiety symptoms over 6 months (24 weeks) of treatment.
大体时间:Baseline to 6 months
|
Anxiety symptoms will be assessing using the Generalized Anxiety Disorder-7 (GAD7),7-item short form, questionnaire to assess severity of anxiety symptoms over a 2-week period. Score range: 0-21, with higher scores indicating a worse outcome. |
Baseline to 6 months
|
|
Change in composite cognitive function over 6 months (24 weeks) of treatment, using a composite cognitive score that incorporates normalized data from all domain-specific cognitive tests.
大体时间:Baseline to 6 months
|
The composite cognitive score will be calculated as the average of Z-scores from the following individual cognitive tests: a) Auditory Verbal Learning Test (AVLT); b) Oral Trail Making Test (OTMT) part A; c) OTMT part B; d) Digit Span Test; and e) Digit Symbol Substitution Test (DSST). The normative mean of each cognitive test will be subtracted from each participant's component test score, and this difference will be divided by the standard deviation for the appropriate normative sample. After scores from individual tests are transformed to Z scores as a common metric based on normative data, the average Z score from all available tests will be calculated to provide a composite Z score. |
Baseline to 6 months
|
合作者和调查者
调查人员
- 首席研究员:Alison Huang, MD、University of California, San Francisco
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2K24AG068601 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.